RSV infant jab reduces serious illness but long-term scheme not cost-effective, says health watchdog

Immunising infants to protect them from the potentially serious respiratory syncytial virus (RSV) infection is safe and significantly reduces hospitalisations – but extending it long-term is not cost effective at the current price, according to a new assessment by the health watchdog.